ONCODESIGN Logo

ONCODESIGN

Developing precision oncology solutions for resistant and metastatic cancers.

ALONC | PA

Overview

Corporate Details

ISIN(s):
FR0011766229
LEI:
9695004HPDBVG72O8851
Country:
France
Address:
20 RUE JEAN MAZEN, 21000 DIJON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oncodesign Precision Medicine (OPM) is a biotechnology company dedicated to developing innovative therapeutic and diagnostic solutions. The company's core mission is to address therapeutic resistance and metastasis in cancer through a precision medicine approach. Utilizing a patient-centric, translational model, OPM focuses on discovering and advancing treatments for patients with resistant and metastatic cancers. The company collaborates with clinicians, service providers, and experts to guide its research and development investments towards meeting significant unmet medical needs in oncology.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-12-13 14:25
Delisting Announcement
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres comm…
French 150.7 KB
2022-12-13 11:17
Major Shareholding Notification
Franchissement de seuils
French 209.0 KB
2022-11-24 08:00
M&A Activity
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 145.1 KB
2022-11-23 17:37
Prospectus
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 724.9 KB
2022-11-23 17:36
M&A Activity
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 2.3 MB
2022-11-08 16:38
M&A Activity
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 2.2 MB
2022-11-08 15:54
Delisting Announcement
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 231.6 KB
2022-11-02 17:28
Prospectus
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 1.0 MB
2022-11-02 17:25
Prospectus
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 506.0 KB
2022-10-26 11:17
Major Shareholding Notification
Franchissement de seuil
French 198.3 KB
2022-10-26 11:16
Major Shareholding Notification
Franchissement de seuils
French 206.0 KB
2022-10-19 08:00
M&A Activity
Inside Information / Operations of the issuer (acquisitions, sales...)
English 340.5 KB
2022-10-19 08:00
M&A Activity
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
French 390.8 KB
2022-10-04 18:00
Delisting Announcement
Inside Information / Other news releases
English 268.6 KB
2022-10-04 18:00
Delisting Announcement
Informations privilégiées / Autres communiqués
French 273.9 KB

Automate Your Workflow. Get a real-time feed of all ONCODESIGN filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ONCODESIGN

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ONCODESIGN via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM

Talk to a Data Expert

Have a question? We'll get back to you promptly.